CHICAGO, Jan. 24, 2023 /PRNewswire/ -- There is latest development in the mRNA vaccines market, as the Chinese bank is trying to entice wealthy customers with mRNA vaccines: Exclusive Report by Cognitive Market Research
Global mRNA Vaccine
Market Report
2025
mRNA Vaccine Market Report 2025 (Global Edition)
As per Cognitive Market Research's latest published report, the Global mRNA vaccine market size was $1.45 Billion in 2022 and it is forecasted to reach $3.86 Billion by 2030. mRNA vaccine Industry's Compound Annual Growth Rate will be 12.8 % from 2023 to 2030. Whereas a Self-amplifying mRNA Vaccines Market Share was 61.25%, a leading type of mRNA Vaccine.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
|
Rating: 4.8 | Review: 5
Share your contact details to receive free updated sample copy/pages of the recently published edition of mRNA Vaccine Market Report 2024.
Global mRNA Vaccine Market Report 2024 Market Size Split by Type (Conventional mRNA Vaccines, Self-amplifying mRNA Vaccines), by Application (Cytomegalovirus (CMV), Influenza, Rabies, Cancer, COVID-19...
As per Cognitive Market Research's latest published report, the Global mRNA vaccine market size was $1.45 Billion in 2022 and it is forecasted to reach $3.86 Billion by 2030. mRNA vaccine Industry's Compound Annual Growth Rate will be 12.8 % from 2023 to 2030. Whereas a Self-amplifying mRNA Vaccines Market Share was 61.25%, a leading type of mRNA Vaccine.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global mRNA Vaccine Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 12.8% |
| Market Split by Type |
|
| Market Split by Application |
|
| Market Split by Route of Administration |
|
| Market Split by End-user |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Report scope is customizable as we have a huge database of mRNA Vaccine industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
mRNA Vaccine Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
mRNA Vaccine Market Report Description
Introduction of mRNA Vaccine
mRNA is a biological substance that is given in a series of shots to protect the body from developing a disease. It works by triggering the immune system to create antibodies. These antibodies then fight bacteria and viruses that cause disease. Most mRNA vaccines are multi-antigen vaccines, where mRNA has advantages over peptide-based vaccines. For more than 30 years, healthcare providers are using this technology to prevent infectious and oncological diseases. They are also studying mRNA vaccines to treat diseases like multiple sclerosis.
Moreover, mRNA vaccines are used to prevent severe illness from COVID-19 infection. Thus, 2020 was a breakout year for mRNA therapeutics with the launch and widespread use of mRNA vaccines for COVID-19.
mRNA Vaccine Market Size
What is Driving mRNA vaccine Industry Growth?
-
Rise in the prevalence of infectious diseases:
Recently, emerging and re-emerging infectious diseases are posing a public health threat across the globe. This era has witnessed a wave of severe infectious disease outbreaks which has had a devastating impact on lives and livelihoods around the globe. It has been studied that increasing resistances, international traveling, the risk of bio-war attacks, and infectious diseases concern the whole world.
The infectious agents not only disrupt cell growth and proliferation but also weaken the immune system which considerably decreases the body’s ability to fight cancer-causing infections. Some viruses, bacteria and parasites also cause chronic inflammation, leading to cancers.
Further, environmental changes, caused by the intensive development of industry, as a result of globalization, which in turn affects human health. It has stimulated high prevalence of infectious diseases. For instance, a high prevalence of influenza results in mild to severe illness and even death. In industrialized countries, most deaths associated with influenza occur among people aged 65 or older.
In such cases, mRNA vaccines are widely used as both RNA and delivery vehicles exhibit intrinsic immunogenicity. By triggering pattern recognition receptors within cells, synthetic RNA leads to the production of type one interferon (IFN). Thus, the rise in the prevalence of infectious diseases drives the market of mRNA vaccines market.
Mounting R&D Investment:
Health is a prime focused parameter for regulatory bodies across the world. With the increasing prevalence of communicable and non-communicable diseases, the rate of mortality has been increased dramatically. Hence the authorities are focusing on improving the healthcare system.
With the increasing healthcare requirements and associated priorities for research and development, governments and companies are investing more monetary funds into the research and development activities. For instance, the United States has invested $194.2 billion in medical and health research and development which was grew by 6.4% from 2017 to 2018.
Fuelled by the successful utilisation of the mRNA Covid-19 vaccines, RNA therapeutics is expected to make larger strides in 2023. Hence, companies are harnessing RNA research through collaborations. Researchers say this has impacted not just companies with clinical stage-products, but also individual academic labs, which will now likely result in more RNA-focused projects in the next few years.
For instance, Sanofi has launched a dedicated vaccines mRNA Center of Excellence and has invested approximately €400 million to accelerate end-to-end R&D of next-generation vaccines, fully financed through resource reallocation.
We have various report editions of mRNA Vaccine Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
mRNA Vaccine Market Insights Video
Top Companies in mRNA Vaccine Market
Competitive Landscape includes company profiling of the key manufacturers listed below. It also provides the key developments such as new product launches, expansion, mergers & acquisitions, partnerships, agreements, joint ventures, business overview, key strategies and financial analysis associated with the key players. Strategy implemented to overcome the COVID-19 Impact will be discussed in the report scope. Key players Financials includes Revenue (USD Million), Gross Margin (%) and Market Share (%) (2019- 2023), S.W.O.T Analysis, (To read more request the sample pages Or speak to analyst/author directly).
Top Companies Market Share in mRNA Vaccine Industry: (In no particular order of Rank)
- Moderna Inc.
- BioNTech SE.
- CureVac SE
- Arcturus Therapeutics Inc.
- Sanofi
- GSK plc
- Ethris
- Pfizer Inc.
- Others
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
The North America mRNA Vaccine Market dominates overall market:
North America has dominated the market of mRNA vaccines in year 2021 owing to the availability of strong R&D activities in U.S. Further, upon the outbreak of pandemic, Government in this region has constantly supported research in the process of development of vaccinations against COVID-19. In December 2020, FDA issued Emergency Use Authorizations for the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine.
As of June 2021, approximately 296 million doses of mRNA COVID-19 vaccines had been administered in the United States. Further, developed healthcare sector stimulates mRNA vaccine market to propel at significant growth rate in North America.
The current report Scope analyzes mRNA Vaccine Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
mRNA Vaccine Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
mRNA Vaccine Market Analysis
Global mRNA Vaccine Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing mRNA Vaccine Industry growth. mRNA Vaccine market has been segmented with the help of its Type, Application Route of Administration, and others. mRNA Vaccine market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Type analysis of mRNA Vaccine market.
Self-amplifying mRNA molecules are large in size. The four extra proteins are the non-structural proteins, usually derived from an alphavirus, that encode a replicase. This allows amplification of the original strand of RNA upon delivery into the cell which yields a much higher amount of protein expression and thus a minimal dose of RNA required. Hence, self-amplifying RNAs are emerging as important vaccine candidates for infectious diseases.
mRNA Vaccine Market Share (%) by Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of mRNA Vaccine Industry. Request a Free Sample PDF!
mRNA Vaccine market, by application
mRNA vaccines basic MOA includes teaching to body cells to make copies of the spike protein. Once, mRNA delivers the instructions, cells break it down and get rid of it. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), emerged in China in December 2019 and quickly spread around the globe. This challenging situation, prompted entities in government, industry, and academia to work together at unprecedented speed to develop safe and effective vaccines. mRNA vaccines have emerged as lead candidates due to their speed of development and high degree of safety and efficacy. Thus, use of mRNA vaccines in COVID-19 will create huge opportunities in the growth of market.
mRNA Vaccine Market Share (%) by Application in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
mRNA Vaccine Route of Administration Segment Analysis
Route of Administration plays a major role extent and quality of immunogenicity. Subcutaneous segment is thus projected to exhibit the fastest market growth during the forecast period as larger volume of injection can be given resulted in high immunogenicity, precluding the need for another vaccine dose. Further it reduces local adverse reactions.
- IV
- Subcutaneous
mRNA Vaccine End-user Segment Analysis
By End-User, hospitals held major market share and it will show maximum share during the forecast period. This can be attributed owing to availability of trained professionals at hospitals drives mRNA vaccines market.
- Hospitals
- Clinics
- Research Centres
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Bio :
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
- The mRNA Vaccines market size is estimated to reach $91.14 Billion by 2029 with growing at CAGR of 6.78% from 2022-2029.
- Increasing investment in Research and development is expected fuel the market in the near future.
- Hospital segment held the major share of total mRNA Vaccines Market in 2022.
- IV was the major contributor with 61.25% Share of total mRNA Vaccine Market in 2021.
- In terms of revenue, Asia Pacific is expected to show fastest growth in the coming years.
Frequently Asked Questions (FAQs)
Rise in the prevalence of infectious diseases
Mounting R&D Investment.
North America is dominating the mRNA Vaccines market followed by APAC.
Study involved in-depth qualitative and quantitative analyses of the market. Moreover, research study involves the use of secondary sources and databases such as key companies’ annual reports, paid & public database, Bloomberg, and Factiva to identify and collect information useful for a technical and market-oriented study of the global mRNA vaccines market. Market value evaluation is done by using top-down as well as bottom-up analysis.
Yes, the report includes a COVID-19 impact analysis.
The report has been analyzed from year 2017 to 2029 in which
2017-2021: Historic Period
2022: Base Year
2023-2029: Forecast Period
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about mRNA Vaccine Market
In a federal lawsuit filed in Delaware, GLAXOSMITHKLINE has accused Pfizer and BioNTech of violating GSK patents pertaining to messenger RNA (mRNA) technology, which is used in the Covid-19 vaccine. GSK alleges that its patent rights in mRNA-vaccine inventions created more than ten years prior to the pandemic are violated by Pfizer and BioNTech's Comirnaty vaccines. Pfizer intends to vigorously defend against GSK's claims and is confident in its intellectual property position regarding Comirnaty. GSK is prepared to licence these patents on commercially reasonable terms to guarantee continuous patient access because it thinks that its patents established the fundamental technology used in Pfizer and BioNTech's Covid-19 mRNA vaccines. The lawsuit is an addition to a string of high-profile US court disputes concerning patent payments for Moderna, BioNTech, and Pfizer vaccines. Spikevax brought in $6.7 billion for Moderna last year, while Pfizer generated $11.2 billion from Comirnaty sales.
Source Link: https://www.reuters.com/business/healthcare-pharmaceuticals/glaxosmithkline-sues-pfizer-biontech-over-covid-19-vaccine-technology-2024-04-25/
China's drugmakers can't sell mRNA shots but haven't quit yet
China is facing challenges in developing vaccines due to idle production sites and a lack of emergency clearances for mRNA COVID injections, which has affected Walvax Biotechnology, CSPC Pharmaceutical Group, and Stemirna Therapeutics. The Chinese firms are not currently producing three of their vaccines intended for the Chinese market, but they have been working on creating mRNA vaccines that have received some approval in Asia. Due to a lack of demand, Stemirna Therapeutics has stopped construction at a proposed vaccination plant in Shanghai. Moderna is establishing manufacturing in Shanghai with the intention of launching up to 15 new mRNA medications in the next five years and advancing up to 50 candidates into clinical trials. Moderna created one of the first mRNA vaccines against COVID in history.
Source Link: https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-drugmakers-cant-sell-mrna-shots-havent-quit-yet-2024-04-19/
Latest Articles about mRNA Vaccine Market
mRNA vaccine technology keeps developing, we can expect considerably more breakthroughs and advancements that will shape the future of immunization and contribute to a healthier, safer world for all.
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
mRNA Vaccine Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Type | Conventional mRNA Vaccines, Self-amplifying mRNA Vaccines |
| Application | Cytomegalovirus (CMV), Influenza, Rabies, Cancer, COVID-19, Others |
| Route of Administration | IV, Subcutaneous |
| End-user | Hospitals, Clinics, Research Centres |
| List of Competitors | Moderna Inc., BioNTech SE., CureVac SE, Arcturus Therapeutics Inc., Sanofi, GSK plc, Ethris, Pfizer Inc., Others |
Expand All
This chapter will help you gain GLOBAL Market Analysis of mRNA Vaccine. Further deep in this chapter, you will be able to review Global mRNA Vaccine Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global mRNA Vaccine Revenue Market Size, Trend Analysis 2019 - 2031
-
1.2 Global mRNA Vaccine Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global mRNA Vaccine Revenue Market Size By Region
-
-
1.3 Global mRNA Vaccine Market Size By Type 2019 -2031
-
1.3.1 Conventional mRNA Vaccines Market Size
-
1.3.2 Self-amplifying mRNA Vaccines Market Size
-
-
1.4 Global mRNA Vaccine Market Size By Application 2019 -2031
-
1.4.1 Cytomegalovirus (CMV) Market Size
-
1.4.2 Influenza Market Size
-
1.4.3 Rabies Market Size
-
1.4.4 Cancer Market Size
-
1.4.5 COVID-19 Market Size
-
1.4.6 Others Market Size
-
-
1.5 Global mRNA Vaccine Market Size By Route of Administration 2019 -2031
-
1.5.1 IV Market Size
-
1.5.2 Subcutaneous Market Size
-
-
1.6 Global mRNA Vaccine Market Size By End-user for 2019 -2031
-
1.6.1 Hospitals Market Size
-
1.6.2 Clinics Market Size
-
1.6.3 Research Centres Market Size
-
-
1.7 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.8 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.8.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.8.2 Global Market Revenue Split By Type
-
1.8.3 Global Market Revenue Split By Application
-
1.8.4 Global Market Revenue Split By Route of Administration
-
1.8.5 Global Market Revenue Split By End-user
-
1.8.6 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
This chapter will help you gain North America Market Analysis of mRNA Vaccine. Further deep in this chapter, you will be able to review North America mRNA Vaccine Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
-
2.1 North America mRNA Vaccine Market Size 2019 - 2031
-
2.1.1 North America mRNA Vaccine Market Size By Country 2019 - 2031
-
2.1.2 North America mRNA Vaccine Market Size by Type 2019 -2031
-
2.1.2.1 North America Conventional mRNA Vaccines Market Size
-
2.1.2.2 North America Self-amplifying mRNA Vaccines Market Size
-
-
2.1.3 North America mRNA Vaccine Market Size by Application 2019 -2031
-
2.1.3.1 North America Cytomegalovirus (CMV) Market Size
-
2.1.3.2 North America Influenza Market Size
-
2.1.3.3 North America Rabies Market Size
-
2.1.3.4 North America Cancer Market Size
-
2.1.3.5 North America COVID-19 Market Size
-
2.1.3.6 North America Others Market Size
-
-
2.1.4 North America mRNA Vaccine Market Size by Route of Administration 2019 -2031
-
2.1.4.1 North America IV Market Size
-
2.1.4.2 North America Subcutaneous Market Size
-
-
2.1.5 North America mRNA Vaccine Market Size by End-user 2019 -2031
-
2.1.5.1 North America Hospitals Market Size
-
2.1.5.2 North America Clinics Market Size
-
2.1.5.3 North America Research Centres Market Size
-
-
This chapter will help you gain Europe Market Analysis of mRNA Vaccine. Further deep in this chapter, you will be able to review Europe mRNA Vaccine Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
-
3.1 Europe mRNA Vaccine Market Size 2019 - 2031
-
3.1.1 Europe mRNA Vaccine Market Size By Country 2019 - 2031
-
3.1.2 Europe mRNA Vaccine Market Size by Type 2019 -2031
-
3.1.2.1 Europe Conventional mRNA Vaccines Market Size
-
3.1.2.2 Europe Self-amplifying mRNA Vaccines Market Size
-
-
3.1.3 Europe mRNA Vaccine Market Size by Application 2019 -2031
-
3.1.3.1 Europe Cytomegalovirus (CMV) Market Size
-
3.1.3.2 Europe Influenza Market Size
-
3.1.3.3 Europe Rabies Market Size
-
3.1.3.4 Europe Cancer Market Size
-
3.1.3.5 Europe COVID-19 Market Size
-
3.1.3.6 Europe Others Market Size
-
-
3.1.4 Europe mRNA Vaccine Market Size by Route of Administration 2019 -2031
-
3.1.4.1 Europe IV Market Size
-
3.1.4.2 Europe Subcutaneous Market Size
-
-
3.1.5 Europe mRNA Vaccine Market Size by End-user 2019 -2031
-
3.1.5.1 Europe Hospitals Market Size
-
3.1.5.2 Europe Clinics Market Size
-
3.1.5.3 Europe Research Centres Market Size
-
-
This chapter will help you gain Asia Pacific Market Analysis of mRNA Vaccine. Further deep in this chapter, you will be able to review Asia Pacific mRNA Vaccine Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific mRNA Vaccine Market Size 2019 - 2031
-
4.1.1 Asia Pacific mRNA Vaccine Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific mRNA Vaccine Market Size by Type 2019 -2031
-
4.1.2.1 Asia Pacific Conventional mRNA Vaccines Market Size
-
4.1.2.2 Asia Pacific Self-amplifying mRNA Vaccines Market Size
-
-
4.1.3 Asia Pacific mRNA Vaccine Market Size by Application 2019 -2031
-
4.1.3.1 Asia Pacific Cytomegalovirus (CMV) Market Size
-
4.1.3.2 Asia Pacific Influenza Market Size
-
4.1.3.3 Asia Pacific Rabies Market Size
-
4.1.3.4 Asia Pacific Cancer Market Size
-
4.1.3.5 Asia Pacific COVID-19 Market Size
-
4.1.3.6 Asia Pacific Others Market Size
-
-
4.1.4 Asia Pacific mRNA Vaccine Market Size by Route of Administration 2019 -2031
-
4.1.4.1 Asia Pacific IV Market Size
-
4.1.4.2 Asia Pacific Subcutaneous Market Size
-
-
4.1.5 Asia Pacific mRNA Vaccine Market Size by End-user 2019 -2031
-
4.1.5.1 Asia Pacific Hospitals Market Size
-
4.1.5.2 Asia Pacific Clinics Market Size
-
4.1.5.3 Asia Pacific Research Centres Market Size
-
-
This chapter will help you gain South America Market Analysis of mRNA Vaccine. Further deep in this chapter, you will be able to review South America mRNA Vaccine Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
-
5.1 South America mRNA Vaccine Market Size 2019 - 2031
-
5.1.1 South America mRNA Vaccine Market Size By Country 2019 - 2031
-
5.1.2 South America mRNA Vaccine Market Size by Type 2019 -2031
-
5.1.2.1 South America Conventional mRNA Vaccines Market Size
-
5.1.2.2 South America Self-amplifying mRNA Vaccines Market Size
-
-
5.1.3 South America mRNA Vaccine Market Size by Application 2019 -2031
-
5.1.3.1 South America Cytomegalovirus (CMV) Market Size
-
5.1.3.2 South America Influenza Market Size
-
5.1.3.3 South America Rabies Market Size
-
5.1.3.4 South America Cancer Market Size
-
5.1.3.5 South America COVID-19 Market Size
-
5.1.3.6 South America Others Market Size
-
-
5.1.4 South America mRNA Vaccine Market Size by Route of Administration 2019 -2031
-
5.1.4.1 South America IV Market Size
-
5.1.4.2 South America Subcutaneous Market Size
-
-
5.1.5 South America mRNA Vaccine Market Size by End-user 2019 -2031
-
5.1.5.1 South America Hospitals Market Size
-
5.1.5.2 South America Clinics Market Size
-
5.1.5.3 South America Research Centres Market Size
-
-
This chapter will help you gain Middle East and Africa Market Analysis of mRNA Vaccine. Further deep in this chapter, you will be able to review Middle East and Africa mRNA Vaccine Market Split by various segments and Country Split.
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa mRNA Vaccine Market Size 2019 - 2031
-
6.1.1 Middle East and Africa mRNA Vaccine Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa mRNA Vaccine Market Size by Type 2019 -2031
-
6.1.2.1 Middle East and Africa Conventional mRNA Vaccines Market Size
-
6.1.2.2 Middle East and Africa Self-amplifying mRNA Vaccines Market Size
-
-
6.1.3 Middle East and Africa mRNA Vaccine Market Size by Application 2019 -2031
-
6.1.3.1 Middle East and Africa Cytomegalovirus (CMV) Market Size
-
6.1.3.2 Middle East and Africa Influenza Market Size
-
6.1.3.3 Middle East and Africa Rabies Market Size
-
6.1.3.4 Middle East and Africa Cancer Market Size
-
6.1.3.5 Middle East and Africa COVID-19 Market Size
-
6.1.3.6 Middle East and Africa Others Market Size
-
-
6.1.4 Middle East and Africa mRNA Vaccine Market Size by Route of Administration 2019 -2031
-
6.1.4.1 Middle East and Africa IV Market Size
-
6.1.4.2 Middle East and Africa Subcutaneous Market Size
-
-
6.1.5 Middle East and Africa mRNA Vaccine Market Size by End-user 2019 -2031
-
6.1.5.1 Middle East and Africa Hospitals Market Size
-
6.1.5.2 Middle East and Africa Clinics Market Size
-
6.1.5.3 Middle East and Africa Research Centres Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1mRNA Vaccine Market Size by Type 2019 -2031
-
7.1.2 Country 1mRNA Vaccine Market Size by Application 2019 -2031
-
7.1.3 Country 1mRNA Vaccine Market Size by Route of Administration 2019 -2031
-
7.1.4 Country 1mRNA Vaccine Market Size by End-user 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
This chapter provides an in-depth analysis of the market share among key competitors of mRNA Vaccine. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global mRNA Vaccine Market Revenue and Share by Key Players
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Moderna Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 BioNTech SE.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 CureVac SE
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Arcturus Therapeutics Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Sanofi
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 GSK plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Ethris
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Pfizer Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Others
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Restraints
-
9.3 Market Trends
-
9.4 Market Opportunity
-
9.5 Technological Road Map (Subject to Data Availability)
-
9.6 Product Life Cycle (Subject to Data Availability)
-
9.7 Consumer Preference Analysis
-
9.8 Market Attractiveness Analysis
-
9.9 PESTEL Analysis
-
9.9.1 Political Factors
-
9.9.2 Economic Factors
-
9.9.3 Social Factors
-
9.9.4 Technological Factors
-
9.9.5 Legal Factors
-
9.9.6 Environmental Factors
-
-
9.10 Industrial Chain Analysis (Subject to Data Availability)
-
9.10.1 Industry Chain Analysis
-
9.10.2 Manufacturing Cost Analysis
-
9.10.3 Supply Side Analysis
-
9.10.3.1 Raw Material Analysis
-
9.10.3.2 Raw Material Procurement Analysis
-
9.10.3.3 Raw Material Price Trend Analysis
-
-
-
9.11 Porter’s Five Forces Analysis
-
9.11.1 Bargaining Power of Suppliers
-
9.11.2 Bargaining Power of Buyers
-
9.11.3 Threat of New Entrants
-
9.11.4 Threat of Substitutes
-
9.11.5 Degree of Competition
-
-
9.12 Patent Analysis (Subject to Data Availability)
-
9.13 ESG Analysis
Segmentation Type Analysis 2019 -2031, will provide market size split by Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Type Analysis 2019 -2031
-
10.1 Conventional mRNA Vaccines
-
10.1.1 Global mRNA Vaccine Revenue Market Size and Share by Conventional mRNA Vaccines 2019 -2031
-
-
10.2 Self-amplifying mRNA Vaccines
-
10.2.1 Global mRNA Vaccine Revenue Market Size and Share by Self-amplifying mRNA Vaccines 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Application Analysis 2019 -2031
-
11.1 Cytomegalovirus (CMV)
-
11.1.1 Global mRNA Vaccine Revenue Market Size and Share by Cytomegalovirus (CMV) 2019 - 2031
-
-
11.2 Influenza
-
11.2.1 Global mRNA Vaccine Revenue Market Size and Share by Influenza 2019 - 2031
-
-
11.3 Rabies
-
11.3.1 Global mRNA Vaccine Revenue Market Size and Share by Rabies 2019 - 2031
-
-
11.4 Cancer
-
11.4.1 Global mRNA Vaccine Revenue Market Size and Share by Cancer 2019 - 2031
-
-
11.5 COVID-19
-
11.5.1 Global mRNA Vaccine Revenue Market Size and Share by COVID-19 2019 - 2031
-
-
11.6 Others
-
11.6.1 Global mRNA Vaccine Revenue Market Size and Share by Others 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Route of Administration Analysis 2019 -2031
-
12.1 IV
-
12.1.1 Global mRNA Vaccine Revenue Market Size and Share by IV 2019 -2031
-
-
12.2 Subcutaneous
-
12.2.1 Global mRNA Vaccine Revenue Market Size and Share by Subcutaneous 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 13 Market Split by End-user Analysis 2019 -2031
-
13.1 Hospitals
-
13.1.1 Global mRNA Vaccine Revenue Market Size and Share by Hospitals 2019 -2031
-
-
13.2 Clinics
-
13.2.1 Global mRNA Vaccine Revenue Market Size and Share by Clinics 2019 -2031
-
-
13.3 Research Centres
-
13.3.1 Global mRNA Vaccine Revenue Market Size and Share by Research Centres 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global mRNA Vaccine market
Chapter 14 Research Findings
-
14.1 Key Takeaways
-
14.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
14.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 mRNA Vaccine Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for mRNA Vaccine Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for mRNA Vaccine Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for mRNA Vaccine Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for mRNA Vaccine Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for mRNA Vaccine Market
mRNA Vaccine Market Infographics
Key Questions Answered By mRNA Vaccine Market Report 2024
| Why Conventional mRNA Vaccines have a significant impact on mRNA Vaccine market? |
| What are the key factors affecting the Conventional mRNA Vaccines and Self-amplifying mRNA Vaccines of mRNA Vaccine Market? |
| What is the CAGR/Growth Rate of Cytomegalovirus (CMV) during the forecast period? |
| By type, which segment accounted for largest share of the global mRNA Vaccine Market? |
| Which region is expected to dominate the global mRNA Vaccine Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
